These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
168 related articles for article (PubMed ID: 2191814)
41. Heparin requires both antithrombin and extrinsic pathway inhibitor for its anticoagulant effect in human blood. Abildgaard U; Lindahl AK; Sandset PM Haemostasis; 1991; 21(4):254-7. PubMed ID: 1794751 [TBL] [Abstract][Full Text] [Related]
42. Plasma antigen levels of the lipoprotein-associated coagulation inhibitor in patient samples. Novotny WF; Brown SG; Miletich JP; Rader DJ; Broze GJ Blood; 1991 Jul; 78(2):387-93. PubMed ID: 2070076 [TBL] [Abstract][Full Text] [Related]
43. The role of tissue factor and tissue factor pathway inhibitor in health and disease states. DelGiudice LA; White GA J Vet Emerg Crit Care (San Antonio); 2009 Feb; 19(1):23-9. PubMed ID: 19691583 [TBL] [Abstract][Full Text] [Related]
44. [Vascular function tests for diagnosis of blood coagulation disorders]. Maruyama I Nihon Naika Gakkai Zasshi; 1991 Jun; 80(6):839-43. PubMed ID: 1919197 [No Abstract] [Full Text] [Related]
45. The coagulation cascade in sepsis. Wang L; Bastarache JA; Ware LB Curr Pharm Des; 2008; 14(19):1860-9. PubMed ID: 18691097 [TBL] [Abstract][Full Text] [Related]
46. Blood coagulation, fibrinolysis and platelet function in women aged 38, 46, 50, 54 and 60. The study of women in Gothenburg 1968-1969. Korsan-Bengtsen K; Bengtsson C; Tibblin E Acta Med Scand; 1973 Jun; 193(6):543-6. PubMed ID: 4721963 [No Abstract] [Full Text] [Related]
48. Blood coagulation factors in the elderly. Hager K; Setzer J; Vogl T; Voit J; Platt D Arch Gerontol Geriatr; 1989; 9(3):277-82. PubMed ID: 2640086 [TBL] [Abstract][Full Text] [Related]
49. Cultured normal human hepatocytes do not synthesize lipoprotein-associated coagulation inhibitor: evidence that endothelium is the principal site of its synthesis. Bajaj MS; Kuppuswamy MN; Saito H; Spitzer SG; Bajaj SP Proc Natl Acad Sci U S A; 1990 Nov; 87(22):8869-73. PubMed ID: 2247459 [TBL] [Abstract][Full Text] [Related]
56. Coagulation and fibrinolysis in human acute lung injury--new therapeutic targets? Ware LB; Bastarache JA; Wang L Keio J Med; 2005 Sep; 54(3):142-9. PubMed ID: 16237276 [TBL] [Abstract][Full Text] [Related]
57. Extrinsic pathway inhibitor (EPI) and the post-heparin anticoagulant effect in tissue thromboplastin induced coagulation. Lindahl AK; Abildgaard U; Larsen ML; Aamodt LM; Nordfang O; Beck TC Thromb Res Suppl; 1991; 14():39-48. PubMed ID: 1658969 [TBL] [Abstract][Full Text] [Related]
58. Purification and properties of heparin-releasable lipoprotein-associated coagulation inhibitor. Novotny WF; Palmier M; Wun TC; Broze GJ; Miletich JP Blood; 1991 Jul; 78(2):394-400. PubMed ID: 2070077 [TBL] [Abstract][Full Text] [Related]
59. [Tissue factor and inhibitor of the blood coagulation pathway in nephrotic syndrome]. Małyszko JS; Małyszko J; Myśliwiec M Pol Arch Med Wewn; 1999 Apr; 101(4):301-5. PubMed ID: 10740407 [TBL] [Abstract][Full Text] [Related]
60. [Basic knowledge on coagulation and fibrinolysis to understand thrombus-formation machinery]. Urano T; Suzuki Y Nihon Rinsho; 2014 Jul; 72(7):1198-205. PubMed ID: 25163308 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]